Search Result

Results for "

HCA.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GPR109A (2) Adenosine Receptor (1) Akt (1) Aminotransferases (Transaminases) (1) Antibiotic (2) Apoptosis (18) Autophagy (4) Bacterial (8) Bcl-2 Family (1) c-Met/HGFR (1) Calcium Channel (2) Carbonic Anhydrase (153) Caspase (1) CDK (5) Cholinesterase (ChE) (12) COX (2) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (2) Endogenous Metabolite (6) ERK (1) Ferroptosis (1) Fungal (1) GABA Receptor (1) Glycosidase (2) HDAC (1) HSV (1) Hydroxycarboxylic Acid Receptor (HCAR) (4) iGluR (2) Integrin (3) Interleukin Related (1) Isotope-Labeled Compounds (5) JNK (1) LOX-1 (1) MAGL (1) Mitochondrial Metabolism (2) MOFs (1) mTOR (3) NAMPT (1) NKCC (3) NOD-like Receptor (NLR) (2) P-glycoprotein (2) p38 MAPK (1) Parasite (2) Phosphodiesterase (PDE) (1) Phospholipase (1) Prostaglandin Receptor (2) Reactive Oxygen Species (ROS) (4) Reference Standards (9) Sodium Channel (1) Tyrosinase (2) VEGFR (5) Wnt (1) β-catenin (1) β-glucuronidase (2)
By Research Areas:	Cancer (97) Cardiovascular Disease (9) Endocrinology (3) Infection (15) Inflammation/Immunology (16) Metabolic Disease (21) Neurological Disease (44)
Click Chemistry:	Azide (1)

183

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: GPR109A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14857

Carotegrast HCA2969	Integrin	Inflammation/Immunology
Carotegrast (HCA2969) is an orally active α4 integrin inhibitor with anti-inflammatory activity. Carotegrast can be used in the research of inflammation-related diseases, such as ulcerative colitis .

HY-32004

Coumalic acid	Endogenous Metabolite Parasite Hydroxycarboxylic Acid Receptor (HCAR)	Infection
Coumalic acid is an inhibitor of human carbonic anhydrase (hCA) (K_I = 0.073 μM for hCA IX; K_I = 0.083 μM for hCA XII). Coumalic acid is a valuable platform compound which can be prepared from malic acid. Coumalic acid can be used in the flavorings, fragrances and cosmetics industries, as polymer components, and pharmaceutical scaffolds. Coumalic acid displays antibronchial and antimalarial activity .

HY-138903

L-Homocysteic acid 1 Publications Verification L-HCA	iGluR	Neurological Disease
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC₅₀: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders .

HY-116141

7-Hydroxycoumarinyl arachidonate 7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate	Phospholipase MAGL	Others
7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer .

HY-100982

(E) -4-Hydroxycrotonic acid trans-4-Hydroxycrotonic acid; trans-γ-Hydroxycrotonic acid; T‐HCA	GABA Receptor	Neurological Disease
(E)-4-Hydroxycrotonic acid (T-HCA) is a high-affinity ligand for GHB binding sites, with a k_i value of 1.1 μM. The introduction of diaryl substituents into (E)-4-Hydroxycrotonic acid significantly enhances its affinity for GHB binding sites, with k_i values ranging from 0.023 to 0.075 μM. (E)-4-Hydroxycrotonic acid holds promise for optimizing GHB ligand structures and assisting in the development of effective three-dimensional pharmacophore models .

HY-163109

Carbonic anhydrase inhibitor 16	Carbonic Anhydrase	Infection
Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase hCA I and hCA II (K_i: 28.5 nM, 2.2 nM) .

HY-179026

HCA-6	Calcium Channel P-glycoprotein Apoptosis Bacterial	Infection Cancer
HCA-6 is a calcium-channel and P-glycoprotein blocker. HCA-6 can induce cancer cells apoptosis and increase anticancer activity of Cisplatin (HY-17394). HCA-6 also exhibits antibacterial activity against Bacillus subtilis. HCA-6 can be used for the research of cancer and infection, such as breast cancer .

HY-147986

hCA I-IN-2	Carbonic Anhydrase	Cancer
hCA I-IN-2 (Compound 6d) is a selective *human carbonic anhydrase I (hCA* I) inhibitor with K_i** values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .

HY-147985

hCA I-IN-1	Carbonic Anhydrase	Cancer
hCA I-IN-1 (Compound 6q) is a *human carbonic anhydrase I (hCA* I) inhibitor with K_i** values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .

HY-155391

hCA/Wnt/β-catenin-IN-1	Carbonic Anhydrase P-glycoprotein Wnt β-catenin	Cancer
hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of *hCA* (K_i: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .

HY-146206

HCAIX-IN-1	Carbonic Anhydrase	Cancer
HCAIX-IN-1 (compound 21e) is a potent and selective HCAIX inhibitor with K_Is of 694.9, 126.6, 3.3, 9.8 nM for hCA I, hCA II, hCA IX, hCA XII, respectively .

HY-152140

hCAII-IN-8	Carbonic Anhydrase	Cancer
hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC₅₀ value of 0.18 μM against hCA II .

HY-150973

hCAII-IN-4	Carbonic Anhydrase β-glucuronidase	Neurological Disease Metabolic Disease Cancer
hCAII-IN-4 (Compound 12j) is a potent hCA II inhibitor with an IC₅₀ of 7.78 μM. hCAII-IN-4 also inhibits β-glucuronidase with an IC₅₀ of 773.9 μM .

HY-175847

hCA-I/hCA-II-IN-2	Carbonic Anhydrase	Cancer
hCA-I/ HCA-II-IN-2 (compound 5 k) is an effective inhibitor of human carbonic anhydrase I (hCA-I) and II (hCA-II). The IC₅₀ for hCA I and hCA II are 89.25 and 54.50 nM respectively .

HY-178017

*BChE/hCA* II-IN-1**	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease
BChE/hCA II-IN-1 (Compound 20) is a dual-functional inhibitor of Butyrylcholinesterase (BChE) and *human carbonic anhydrase II (hCA* II) with IC₅₀*s of 76.50 and 10.69  μM for BChE and hCA* II, respectively. BChE/hCA II-IN-1 can be used for neurodegenerative diseases like Alzheimer's and glaucoma research .

HY-150570

Carbonic anhydrase inhibitor 14	Carbonic Anhydrase CDK	Cancer
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with K_i values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC₅₀ of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .

HY-101136

Dealanylascamycin AT-265	Antibiotic Carbonic Anhydrase Bacterial	Infection
Dealanylascamycin (AT-265) (Compound 2) is a nucleoside antibiotic. AT 265 is a carbonic anhydrase (CA) inhibitor, with K_i values of 167, 65.2, 234, and 143 nM for hCA I, hCA II, hCA IV, and hCA IX respectively. Dealanylascamycin is the active form of Ascamycin (HY-121071). Dealanylascamycin exhibits broad-spectrum antibacterial activity and is effective against pathogenic bacteria such as Xanthomonas citri (MIC = 0.4 μg/mL). Dealanylascamycin has high cytotoxicity .

HY-W031519

Chloraminophenamide	Carbonic Anhydrase	Cardiovascular Disease
Chloraminophenamide (Compound 14) is a carbonic anhydrase inhibitor, with *K_is of 75, 160 and 8400 nM for hCA* II, bCA IV and hCA I, respectively. Chloraminophenamide has the potential for antiglaucoma research .**

HY-174835

hCA-I/hCA-II-IN-1	Carbonic Anhydrase	Cardiovascular Disease
hCA-I/hCA-II-IN-1 (Compound P4) is a potent dual human carbonic anhydrase I (hCA-I) and human carbonic anhydrase II (hCA-II) inhibitor with K_i values of 0.22 μM and 0.33 μM, respectively. hCA-I/hCA-II-IN-1 can be used in research on diseases related to CA enzymes such as glaucoma, hypertension, and ulcers .

HY-175245

hCA-IN-1	Carbonic Anhydrase	Cancer
hCA-IN-1 (Compound 5u) is an *hCA* inhibitor with K_i values of 159.2, 4.8, 15.5, and 2 nM against hCA I, hCA II, hCA IX, and hCA XII, respectively. hCA-IN-1 exhibits broad-spectrum anticancer activity against melanoma, breast, and colon cancer cells. ADME predictions indicate that hCA-IN-1 has good solubility and oral bioavailability. hCA-IN-1 can be used in tumor research .

HY-158372

hCA I-IN-3	Carbonic Anhydrase	Cancer
hCA I-IN-3 (compound 24), an aryl ether derivative, is a potent carbonic anhydrase inhibitor. hCA I-IN-3 can inhibit carbonic anhydrase hCA I and hCA II isoenzymes, with IC₅₀ values of 4.77 and 9.66 nM, respectively. hCA I-IN-3 can be used for cancer research .

HY-149402

hCA XII-IN-6	Carbonic Anhydrase	Cancer
hCA XII-IN-6 (compound 4d) is a potent hCA XII inhibitor with a K_i value of 84.2 nM. hCA XII-IN-6 has anti-proliferative activity. hCA XII-IN-6 can be used in research of cancer .

HY-155760

hCA/VEGFR-2-IN-3	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC₅₀=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .

HY-155763

hCA/VEGFR-2-IN-4	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC₅₀=0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .

HY-155758

hCA/VEGFR-2-IN-2	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC₅₀=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .

HY-147799

hCA XII/II/IX-IN-1	Carbonic Anhydrase	Cancer
hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonic anhydrase (hCA) inhibitor with IC₅₀ values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity .

HY-169962

hCA I-IN-4	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease Cancer
hCA I-IN-4 (Compound 14) is the inhibitor for carbonic anhydrase and cholinesterase, that inhibits hCA I, hCA II, AChE, and BChE with K_i of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nMrespectively. hCA I-IN-4 exhibits cytotoxicity in BT-549 with IC₅₀ of 16.59 μM .

HY-163710

hCA/VEGFR-2-IN-5	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2 IN-5 (compound 9) is an indolone-phenylsulfonamide and a potential dual inhibitor of cancer-related hCA IX/XII and VEGFR-2. The IC₅₀ values of hCA/VEGFR-2-IN-5 for VEGFR-2, hCA IX and hCA XII are 0.38 μM, 40 and 3.2 nM, respectively. hCA/VEGFR-2-IN-5 has antitumor activity .

HY-147956

hCA VB-IN-1	Carbonic Anhydrase	Neurological Disease Metabolic Disease
hCA VB-IN-1 (compound 15) is a potent and selective hCA VB (carbonic anhydrase) inhibitor, with a K_I of 515.7 nM .

HY-149012

*AChE/hCA* I/II-IN-1**	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease Endocrinology
AChE/hCA I/II-IN-1 (Compound 6) is a potent inhibitor of *AChE/Hca* with IC₅₀ values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used for the rsearch for glaucoma, Alzheimer's disease, diabetes .

HY-155694

hCA/VEGFR-2-IN-1	Carbonic Anhydrase VEGFR	Cancer
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual Carbonic Anhydrase(CA) IX/XII with K_i values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2 inhibitor with IC₅₀ values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity .

HY-170560

*AChE/hCA* I-IN-1**	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease
AChE/hCA I-IN-1 (Compound L3) is the inhibitor for acetylcholinesterase (AChE) and carbonic anhydrase (CA), that inhibits AChE, hCA I and hCA II with IC₅₀ of 302, 265 and 283 nM, respectively .

HY-146979

*hA2A/hCA* XII modulator 1**	Adenosine Receptor Carbonic Anhydrase	Cancer
hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA_2A adenosine receptor (hA_2AAR) antagonist with K_is of 6.4 nM, 4.819 μM, >30 μM for hA_2AAR, hA₁AR, hA₃AR, respectively. hA2A/hCA XII modulator 1 is a potent *human carbonic anhydrase XII (hCA* XII) inhibitor with K_i*s of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA* XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .

HY-151578

*DPP IV/hCA* II-IN-1**	Dipeptidyl Peptidase Carbonic Anhydrase	Metabolic Disease
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) inhibitor with an IC₅₀ value of 0.049 μM for DPP IV and with K_i values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively .

HY-146007

hCAIX-IN-17	Carbonic Anhydrase	Cancer
hCA IX-IN-1 (Compound 6f) is a human carbonic anhydrase (hCA) inhibitor with K_i values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity .

HY-146008

hCAII-IN-3	Carbonic Anhydrase	Cancer
hCAII-IN-3 (Compound 16) is a human carbonic anhydrase (hCA) inhibitor with K_i values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity .

HY-146355

hCAII-IN-2	Carbonic Anhydrase	Cancer
hCAII-IN-2 (Compound 11f) is a cytosolic human carbonic anhydrase (hCA) inhibitor with K_i values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively .

HY-144641

Carbonic anhydrase inhibitor 7	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonic anhydrase (hCA), with K_is of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .

HY-144640

Carbonic anhydrase inhibitor 6	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonic anhydrase (hCA), with K_is of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .

HY-132156

Carbonic anhydrase inhibitor 22	Carbonic Anhydrase	Neurological Disease
Carbonic anhydrase inhibitor 22 (Compd 2g), a sulfonamide carbonic anhydrase inhibitor, with K_i values of 762 nM (hCA I), 20.3 nM (hCA II), 8.3 nM (hCA VII), 17.9 nM (hCA IX) and 10.5 nM (hCA XII), repectively .

HY-157135

hCAIX-IN-19	Carbonic Anhydrase	Cancer
hCAIX-IN-19 is a sulfonamides inhibitor against hCA IX with an inhibition constant (K_I) of 6.2 nM and show good selectivity over hCA I (hCA I/ hCA IX = 117) .

HY-149329

hCAIX/VII-IN-1	Carbonic Anhydrase	Neurological Disease Cancer
hCAIX/VII-IN-1 is a selective hCA VII/IX inhibitor. hCAIX/VII-IN-1 inhibit hCAⅠ, hCAⅡ, hCAⅣ, hCAⅦ and hCAⅨ with K_i values of 336.2 nM,185.8 nM, 1055 nM, 35.6 nM and 28.0 nM, respectively. hCAIX/VII-IN-1 can be used for the research of cancer and neurological diseases .

HY-144639

Carbonic anhydrase inhibitor 5	Carbonic Anhydrase	Infection Inflammation/Immunology Cancer
Carbonic anhydrase inhibitor 5 is a potent and selective human carbonic anhydrase (hCA) inhibitor with IC₅₀s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively .

HY-156169

hCAIX/XII-IN-7	Carbonic Anhydrase	Cancer
hCAIX/XII-IN-7 (compound 3e) is a potent hCA IX and XII inhibitor with K_is of 3.2 nM, 9.2 nM, 503.7 nM and 59 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. hCAIX/XII-IN-7 has the potential for hypoxic tumors research .

HY-163268

Carbonic anhydrase inhibitor 18	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 18 (Compound 9) is a human carbonic anhydrase (hCA) isoform inhibitor, with K_is of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 18 can be used for the research of cancer .

HY-162063

hCAIX/XII-IN-9	Carbonic Anhydrase	Inflammation/Immunology Cancer
hCAIX/XII-IN-9 (compound 8) is a potent carbonic anhydrase (CA) inhibitor with K_i values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .

HY-147829

hCAXII-IN-2	Carbonic Anhydrase	Cancer
hCAXII-IN-2 (compound 5i) is a potent *human carbonic anhydrase XII (hCA* XII)** and hCA IX inhibitor with K_i values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II .

HY-161374

Carbonic anhydrase inhibitor 20	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 20 (compound 11) is an inhibitor of piperazinosulfonamide carbonic anhydrase (Carbonic Anhydrase). The Ki of Carbonic anhydrase inhibitor 20 for hCA I, hCA II, hCA IX, and hCA XII are 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM respectively .

HY-148135

hCAI/II-IN-6	Carbonic Anhydrase	Neurological Disease
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with K_i values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .

HY-169163

BChE-IN-36	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
hBChE-IN-4 (compound 40) is a potent *hCA* activator and BChE inhibitor with K_A values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC₅₀ values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .

Cat. No.	Product Name	Target	Research Area

HY-138903

L-Homocysteic acid 1 Publications Verification L-HCA	iGluR	Neurological Disease
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC₅₀: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-118716

PhIP 1 Publications Verification 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine	Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	Others
PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is the most abundant of generation of heterocyclic amines (HCA), resulted in the cooking of meat . DNA damaging and mutagenic activities. PhIP also has oestrogenic activity that could contribute to its tissue specific carcinogenicity .

HY-W015560

3,5-Dihydroxybenzoic acid	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Tyrosinase Hydroxycarboxylic Acid Receptor (HCAR)
3,5-Dihydroxybenzoic acid a potential biomarker for the consumption of many food products, including beer, nuts, peanut, and pulses. 3,5-Dihydroxybenzoic acid is the agonist for hydroxycarboxylic acid receptor 1 (HCA1, also known as GPR81) that inhibits lipolysis in adipocytes. 3,5-Dihydroxybenzoic acid is the competitive inhibitor for tyrosine phenol-lyase (TPL), exhibits an affinity of K_i=25.7 μM. 3,5-Dihydroxybenzoic acid is orally active .

HY-32004

Coumalic acid	Structural Classification Liliaceae Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Smilacis Glabrae Rhizoma Plants Disease Research Fields Source Classification	Endogenous Metabolite Parasite Hydroxycarboxylic Acid Receptor (HCAR)
Coumalic acid is an inhibitor of human carbonic anhydrase (hCA) (K_I = 0.073 μM for hCA IX; K_I = 0.083 μM for hCA XII). Coumalic acid is a valuable platform compound which can be prepared from malic acid. Coumalic acid can be used in the flavorings, fragrances and cosmetics industries, as polymer components, and pharmaceutical scaffolds. Coumalic acid displays antibronchial and antimalarial activity .

HY-W008343

1,3-Dimethyluracil	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with K_i of 316.2 μM and 166.4 μM, respectively .

HY-W015560R

3,5-Dihydroxybenzoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Tyrosinase Hydroxycarboxylic Acid Receptor (HCAR)
3,5-Dihydroxybenzoic acid (Standard) is the analytical standard of 3,5-Dihydroxybenzoic acid. This product is intended for research and analytical applications. 3,5-Dihydroxybenzoic acid a potential biomarker for the consumption of many food products, including beer, nuts, peanut, and pulses. 3,5-Dihydroxybenzoic acid is the agonist for hydroxycarboxylic acid receptor 1 (HCA1, also known as GPR81) that inhibits lipolysis in adipocytes. 3,5-Dihydroxybenzoic acid is the competitive inhibitor for tyrosine phenol-lyase (TPL), exhibits an affinity of K_i=25.7 μM. 3,5-Dihydroxybenzoic acid is orally active .

HY-N2682A

(E)-Dehydrodiconiferyl alcohol	Monophenols Glycine soya Classification of Application Fields Lignans Phenols Cyamopsis tetragonoloba (L.) Taub. Phenylpropanoids Plants Compositae Disease Research Fields Cancer Source Classification	Carbonic Anhydrase
(E)-Dehydrodiconiferyl alcohol behaves as good hCA IX and hCA XII dual inhibitors . And (E)-Dehydrodiconiferyl alcohol suppresses the NF-κB nuclear translocation in connective tissue of healing area .

HY-W008343R

1,3-Dimethyluracil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively .

HY-N19401

Vescalagin	Structural Classification Phenols Polyphenols Myrciaria dubia (Kunth) McVaugh Myrtaceae Plants Source Classification	Cholinesterase (ChE) Carbonic Anhydrase Glycosidase JNK p38 MAPK
Vescalagin is a hexahydroxyphenol. Vescalagin is isolable from Camu-camu (Myrciaria dubia) and immature wax apple fruits. Vescalagin exhibits inhibitory activity against a variety of enzymes, with a K_i value of 5.87 nM against AChE, 3.89 nM against BChE, 11.75 nM against hCA I, 16.23 nM against hCA II, and 16.08 nM against α-glucosidase. Vescalagin inhibits hCA I, hCA II and α-glucosidase in a non-competitive manner. Vescalagin downregulates JNK/p38 MAPK to protect pancreatic β-cells and improve insulin secretion in methylglyoxal-treated rats. Vescalagin reduces hyperglycemia and hypertriglyceridemia in rats fed a high-fructose diet. Vescalagin possesses anti-inflammatory and antioxidant properties .

Species:	Human (4)
Tag:	SUMO (1) His (3) GST (1)
Source:	Sf9 insect cells (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703310

	KLHDC2 Protein, Human (sf9, His, GST) HCA33	Human	Sf9 insect cells
	KLHDC2 Protein, Human (sf9, His, GST) is the recombinant human-derived KLHDC2, expressed by sf9 insect cells , with His, GST labeled tag. ,

HY-P703461

	KLHDC2/EloB/EloC Protein, Human (Active, sf9, His, GST) HCA33	Human	Sf9 insect cells
	KLHDC2/EloB/EloC Protein, Human (Active, sf9, His, GST) is the recombinant human-derived KLHDC2/EloB/EloC, expressed by sf9 insect cells , with His, GST labeled tag. ,

HY-P703017

	TPX2 Protein, Human (sf9, His) C20orf1; C20orf2; DIL2; HCA519	Human	Sf9 insect cells
	TPX2 Protein, Human (sf9, His) is the recombinant human-derived TPX2, expressed by Sf9 insect cells , with His labeled tag. ,

HY-P71608

	TGS1 Protein, Human (His-SUMO) Cap specific guanine N2 methyltransferase; Cap-specific guanine-N2 methyltransferase; CLL associated antigen KW 2; CLL-associated antigen KW-2; DKFZp762A163; FLJ22995; HCA137; Hepatocellular carcinoma associated antigen 137; Hepatocellular carcinoma-associated antigen 137; NCOA6IP; Nuclear receptor coactivator 6 interacting protein; Nuclear receptor coactivator 6-interacting protein; PIMT; PIPMT; PRIP interacting protein PIPMT; PRIP interacting protein with methyltransferase domain; PRIP interacting protein with methyltransferase motif; PRIP-interacting protein with methyltransferase motif; SEREX defined; TGS 1; Tgs1; TGS1_HUMAN; Trimethylguanosine synthase; Trimethylguanosine synthase homolog (S. cerevisiae); Trimethylguanosine synthase homolog	Human	E. coli
	TGS1 protein catalyzes the conversion of the 7-monomethylguanosine (m(7)G) cap of small nuclear RNA (snRNA) and small nucleolar RNA (snoRNA) into 2, 2,7-trimethylguanosine (m( 2,2,7)G) Cap structure. The enzyme shows specificity for guanine, with N7 methylation occurring before N2 methylation during the modification process. TGS1 Protein, Human (His-SUMO) is the recombinant human-derived TGS1 protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0782S

Acetazolamide-d3
Acetazolamide-d₃ is deuterium labeled Acetazolamide (HY-B0782). Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC₅₀ of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .

HY-118716S

PhIP-d3

PhIP-d₃ (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-d₃) is the deuterium labeled PhIP (HY-118716). PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is the most abundant of generation of heterocyclic amines (HCA), resulted in the cooking of meat . DNA damaging and mutagenic activities. PhIP also has oestrogenic activity that could contribute to its tissue specific carcinogenicity .

HY-B0124S2

Zonisamide-13C6

Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0782S1

Acetazolamide-13C2,d3
Acetazolamide- ¹³C₂,d₃ is the ¹³C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC₅₀ of 30 nM for hCA IX . Diuretic effects .

HY-B0124S3

Zonisamide-15N,d4

Zonisamide- ¹⁵N,d₄ is the ¹⁵N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

Host:	Mouse (4) Rabbit (5)
Reactivity:	Human (9) Rat (4) Mouse (4) Monkey (2) Dog (2)
Application:	IHC-P (6) ICC/IF (4) WB (3) FC (2)
Isotype:	IgG (5) IgG2b (4)
Conjugation:	Non-conjugated (9)
Clonality:	Monoclonal (5) Recombinant (3)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P88699

	FAM119A Antibody (YA8383) FAM119A; HCA557b; HSPA-KMT	IHC-P, FC	Human, Mouse, Rat
	FAM119A Antibody (YA8383) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to FAM119A.

HY-P88699A

	FAM119A Antibody (YA8383)(PBS only) FAM119A; HCA557b; HSPA-KMT	IHC-P, FC	Human, Mouse, Rat
	FAM119A Antibody (YA8383) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to FAM119A.

HY-P88428

	PECI Antibody (YA8112) ACBD2; dJ1013A10.3; DRS-1; DRS1; HCA88; PECI	IHC-P, ICC/IF	Human, Dog, Rat, Monkey, Mouse
	PECI Antibody (YA8112) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PECI.

HY-P88428A

	PECI Antibody (YA8112)(PBS only) ACBD2; dJ1013A10.3; DRS-1; DRS1; HCA88; PECI	IHC-P, ICC/IF	Human, Dog, Rat, Monkey, Mouse
	PECI Antibody (YA8112) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PECI.

HY-P81369

	MAGEC2 Antibody (YA1114) CT10,MAGE-C2 antigen,MAGE-E1 antigen,MAGEC2,HCA587, MAGEE1	IHC-P	Human
	MAGEC2 Antibody (YA1114) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAGEC2.

HY-P81369A

	MAGEC2 Antibody (YA1114)(PBS only) CT10,MAGE-C2 antigen,MAGE-E1 antigen,MAGEC2,HCA587, MAGEE1	IHC-P	Human
	MAGEC2 Antibody (YA1114) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAGEC2.

HY-P83540

	TPX2 Antibody (YA3285) DIL2; p100; DIL-2; HCTP4; FLS353; HCA519; REPP86; C20orf1; C20orf2; GD:C20orf1	WB, ICC/IF	Human
	TPX2 Antibody (YA3285) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TPX2.

HY-P83540A

	TPX2 Antibody (YA3285)(PBS only) DIL2; p100; DIL-2; HCTP4; FLS353; HCA519; REPP86; C20orf1; C20orf2; GD:C20orf1	WB, ICC/IF	Human
	TPX2 Antibody (YA3285) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TPX2.

HY-P87381

	MAGED2/BCG1 Antibody (YA7064) 11B6 antibody; BCG 1 antibody; BCG-1 antibody; Breast cancer-associated gene 1 protein antibody; HCA10 antibody; Hepatocellular carcinoma-associated protein JCL-1 antibody; JCL 1 antibody; MAGD2_HUMAN antibody; MAGE D antibody; MAGE D2 antigen antibody	WB	Human
	MAGED2/BCG1 Antibody (YA7064) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MAGED2/BCG1.